# A Single Rising Dose Study of MK-8150 (MK-8150-001)

> **NCT01590810** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 34 (actual)

## Conditions studied

- Hypertension
- Isolated Systolic Hypertension (ISH)

## Interventions

- **DRUG:** MK-8150 2.0 mg
- **DRUG:** MK-8150 10 mg
- **DRUG:** MK-8150 40 mg
- **DRUG:** MK-8150 90 mg
- **DRUG:** MK-8150 5.0 mg
- **DRUG:** MK-8150 20 mg
- **DRUG:** MK-8150 60 mg
- **DRUG:** MK-8150 120 mg
- **DRUG:** MK-8150 160 mg
- **DRUG:** MK-8150 320 mg
- **DRUG:** MK-8150 600 mg
- **DRUG:** MK-8150 900 mg
- **DRUG:** MK-8150 1200 mg
- **DRUG:** Placebo for MK-8150
- **DRUG:** MK-8150 50 mg
- **DRUG:** MK-8150 100 mg
- **DRUG:** MK-8150 200 mg
- **DRUG:** MK-8150 400 mg
- **DRUG:** MK-8150 500 mg

## Key facts

- **NCT ID:** NCT01590810
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-07
- **Primary completion:** 2013-01-24
- **Final completion:** 2013-02-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2018-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01590810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01590810, "A Single Rising Dose Study of MK-8150 (MK-8150-001)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01590810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*